



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

April 2020





© 2020 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8515  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

April 2020

N = 7421



Health Authority	Male	Female	All
FRASER	1443	450	1893
INTERIOR	415	101	516
NORTHERN	133	94	227
VANCOUVER COASTAL	3359	451	3810
VANCOUVER ISLAND	786	157	943
	<b>6136</b>	<b>1253</b>	<b>7389</b>
		<b>Unknown/not stated:</b>	<b>32</b>
		<b>Total:</b>	<b>7421</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (April 2015 - April 2020)





### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (April 2015 - April 2020)








1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (April 2015 - April 2020)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (April 2015 - April 2020)






### 1.6 Percent Distribution of Active Participants by CD4 Count (April 2015 - April 2020)






### 1.7 Percent Distribution of Inactive Participants by CD4 Count (April 2015 - April 2020)






### 1.8 Active and Inactive Participants (April 2015 - April 2020)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (April 2015 - April 2020)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (April 2015 - April 2020)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(April 2015 - April 2020)








1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT  
(April 2015 - April 2020)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(April 2015 - April 2020)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (April 2015 - April 2020)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(April 2015 - April 2020)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (April 2015 - April 2020)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(April 2015 - April 2020)






1.18 Baseline CD4 for Antiretroviral First Starts (April 2015 - April 2020)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(April 2015 - April 2020)








### 1.20 Cumulative Resistance Testing Results by Resistance Category (April 2015 - April 2020)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (April 2015 - April 2020)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	28	5	0	5	2	580	5	<40	3
1988	29	6	0	6	4	325	6	<40	3
1989	27	52	1	53	34	460	50	<40	3
1990	26	53	1	54	32	520	50	<40	3
1991	26	37	3	40	20	555	37	<40	3
1992	26	62	5	67	39	640	64	<40	3
1993	25	126	16	142	113	550	130	<40	3
1994	23	79	12	91	61	550	83	<40	3
1995	23	131	22	153	111	530	139	<40	3
1996	21	330	53	383	256	554	343	<40	3
1997	19	268	35	303	213	630	273	<40	3
1998	18	192	45	237	168	585	214	<40	3
1999	19	157	40	197	139	540	175	<40	3
2000	19	120	33	153	107	620	138	<40	3
2001	18	116	28	144	103	580	128	<40	3
2002	17	121	27	148	107	580	135	<40	3
2003	17	148	31	179	120	648	163	<40	3
2004	15	152	38	190	133	600	167	<40	3
2005	15	185	47	232	167	600	205	<40	3
2006	14	185	43	228	164	590	207	<40	3
2007	13	245	49	294	207	590	257	<40	3
2008	12	273	70	343	249	650	310	<40	3
2009	11	306	64	370	254	650	328	<40	3
2010	10	280	74	354	250	655	303	<40	3
2011	9	332	75	407	292	685	357	<40	3
2012	8	268	65	333	237	690	296	<40	3
2013	7	266	70	336	229	650	289	<40	3
2014	6	286	55	341	228	735	296	<40	3
2015	5	291	42	333	240	665	289	<40	3
2016	4	281	56	337	228	680	281	<40	3
2017	3	233	36	269	202	670	242	<40	3
2018	2	210	55	265	193	650	238	<40	3

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	1	249	49	298	246	590	280	<40	3
2020	0	97	20	117	100	610	108	<40	3
<b>Total:</b>		<b>6142</b>	<b>1260</b>	<b>7402</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7393	788	2456	<40	2145	610
FEB-2019	7368	797	1854	<40	1583	620
MAR-2019	7407	790	2085	<40	1753	610
APR-2019	7358	797	2141	<40	1746	610
MAY-2019	7416	792	2127	<40	1766	620
JUN-2019	7359	803	1926	<40	1594	620
JUL-2019	7371	812	2111	<40	1695	620
AUG-2019	7366	809	2106	<40	1621	600
SEP-2019	7339	806	2012	<40	1568	600
OCT-2019	7390	785	2140	<40	1743	620
NOV-2019	7343	780	2026	<40	1579	630
DEC-2019	7344	777	1700	<40	1284	610
JAN-2020	7358	774	2226	<40	1700	610
FEB-2020	7332	778	1883	<40	1394	627
MAR-2020	7392	768	1631	<40	1154	620
APR-2020	7421	770	770	<40	530	600

### Definitions:

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	1459	3449	73	73	65	350
FEB-2019	1490	3368	75	108	66	590
MAR-2019	1458	3509	74	636	61	400
APR-2019	1497	3395	81	<50	71	480
MAY-2019	1443	3650	78	87	69	450
JUN-2019	1504	3422	79	<40	71	550
JUL-2019	1492	3497	71	<40	58	530
AUG-2019	1512	3451	81	<40	68	515
SEP-2019	1541	3320	95	<40	78	580
OCT-2019	1482	3624	81	102	69	470
NOV-2019	1502	3575	69	<40	59	560
DEC-2019	1487	3659	58	<40	49	480
JAN-2020	1461	3798	71	255	45	460
FEB-2020	1500	3656	71	<40	57	480
MAR-2020	1455	3866	50	<40	32	495
APR-2020	1426	4017	24	71	17	570

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7364	1459	14	20	191	159	35	13564
FEB-2019	7349	1490	7	16	160	181	-15	13593
MAR-2019	7371	1458	15	13	187	150	22	13613
APR-2019	7325	1497	10	15	152	182	-46	13641
MAY-2019	7389	1443	11	21	197	137	64	13683
JUN-2019	7330	1504	14	13	137	191	-59	13704
JUL-2019	7344	1492	13	13	181	164	14	13727
AUG-2019	7338	1512	12	18	170	175	-6	13763
SEP-2019	7311	1541	14	15	181	203	-27	13790
OCT-2019	7324	1482	3	13	223	150	13	13819
NOV-2019	7318	1502	9	17	165	170	-6	13852
DEC-2019	7314	1487	8	12	164	156	-4	13879
JAN-2020	7332	1461	9	12	181	154	18	13902
FEB-2020	7302	1500	12	19	141	171	-30	13938
MAR-2020	7366	1455	14	23	213	154	64	13974
APR-2020	7402	1426	11	9	160	122	36	13999

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6800	485	53	<b>7393</b>	0.74%	91.98%	6.56%	0.72%	<b>100.00%</b>
FEB-2019	54	6775	490	49	<b>7368</b>	0.73%	91.95%	6.65%	0.67%	<b>100.00%</b>
MAR-2019	60	6808	489	50	<b>7407</b>	0.81%	91.91%	6.60%	0.68%	<b>100.00%</b>
APR-2019	57	6764	489	48	<b>7358</b>	0.77%	91.93%	6.65%	0.65%	<b>100.00%</b>
MAY-2019	56	6824	491	45	<b>7416</b>	0.76%	92.02%	6.62%	0.61%	<b>100.00%</b>
JUN-2019	58	6772	481	48	<b>7359</b>	0.79%	92.02%	6.54%	0.65%	<b>100.00%</b>
JUL-2019	61	6773	489	48	<b>7371</b>	0.83%	91.89%	6.63%	0.65%	<b>100.00%</b>
AUG-2019	60	6775	481	50	<b>7366</b>	0.81%	91.98%	6.53%	0.68%	<b>100.00%</b>
SEP-2019	57	6745	486	51	<b>7339</b>	0.78%	91.91%	6.62%	0.69%	<b>100.00%</b>
OCT-2019	61	6789	488	52	<b>7390</b>	0.83%	91.87%	6.60%	0.70%	<b>100.00%</b>
NOV-2019	60	6747	486	50	<b>7343</b>	0.82%	91.88%	6.62%	0.68%	<b>100.00%</b>
DEC-2019	61	6757	478	48	<b>7344</b>	0.83%	92.01%	6.51%	0.65%	<b>100.00%</b>
JAN-2020	59	6758	485	56	<b>7358</b>	0.80%	91.85%	6.59%	0.76%	<b>100.00%</b>
FEB-2020	58	6739	476	59	<b>7332</b>	0.79%	91.91%	6.49%	0.80%	<b>100.00%</b>
MAR-2020	60	6795	486	51	<b>7392</b>	0.81%	91.92%	6.57%	0.69%	<b>100.00%</b>
APR-2020	61	6827	483	50	<b>7421</b>	0.82%	92.00%	6.51%	0.67%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)







**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	8 23%	3467 48%	7 20%	3254 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3358 47%
FEB-2019	13 45%	3457 48%	12 41%	3256 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	541 8%	13 45%	3306 46%
MAR-2019	6 30%	3470 48%	6 30%	3274 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3305 46%
APR-2019	12 43%	3469 48%	12 43%	3278 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3245 45%
MAY-2019	14 34%	3498 48%	14 34%	3308 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	23 56%	3258 45%
JUN-2019	3 14%	3479 49%	3 14%	3291 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	608 8%	16 76%	3199 45%
JUL-2019	8 36%	3504 49%	8 36%	3325 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 5%	625 9%	13 59%	3178 44%
AUG-2019	14 39%	3515 49%	12 33%	3340 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	630 9%	20 56%	3144 44%
SEP-2019	5 19%	3494 49%	5 19%	3318 46%	0 0%	39 1%	0 0%	1 0%	0 0%	1 0%	5 19%	653 9%	17 63%	3122 44%
OCT-2019	4 14%	3513 49%	2 7%	3331 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 4%	668 9%	23 82%	3143 44%
NOV-2019	8 24%	3458 48%	7 21%	3281 46%	1 3%	37 1%	0 0%	1 0%	0 0%	1 0%	6 18%	728 10%	19 58%	3114 44%
DEC-2019	1 4%	3437 48%	1 4%	3259 46%	0 0%	37 1%	0 0%	1 0%	0 0%	1 0%	13 48%	855 12%	13 48%	3052 43%
JAN-2020	2 9%	3403 47%	2 9%	3227 45%	0 0%	34 0%	0 0%	1 0%	0 0%	0 0%	9 39%	1024 14%	12 52%	2963 41%
FEB-2020	3 8%	3354 47%	3 8%	3182 45%	0 0%	33 0%	0 0%	1 0%	0 0%	0 0%	16 44%	1169 16%	17 47%	2826 40%
MAR-2020	5 14%	3327 46%	5 14%	3162 44%	1 3%	34 0%	0 0%	1 0%	0 0%	0 0%	20 56%	1326 18%	11 31%	2722 38%
APR-2020	6 24%	3303 46%	5 20%	3141 43%	1 4%	35 0%	0 0%	0 0%	0 0%	0 0%	8 32%	1405 19%	11 44%	2645 37%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial		All	
JAN-2019	27	77%	3697	51%
FEB-2019	16	55%	3674	51%
MAR-2019	14	70%	3702	51%
APR-2019	16	57%	3662	51%
MAY-2019	27	66%	3689	51%
JUN-2019	18	86%	3644	51%
JUL-2019	14	64%	3651	51%
AUG-2019	22	61%	3626	51%
SEP-2019	22	81%	3623	51%
OCT-2019	24	86%	3664	51%
NOV-2019	25	76%	3672	51%
DEC-2019	26	96%	3714	52%
JAN-2020	21	91%	3763	52%
FEB-2020	33	92%	3782	53%
MAR-2020	30	83%	3858	54%
APR-2020	19	76%	3896	54%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	6 0%	1 8%	1097 40%	11 92%	1475 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1069 40%	9 82%	1472 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1053 39%	3 60%	1486 55%	0 0%	132 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1027 39%	7 70%	1477 56%	2 20%	132 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1033 39%	11 92%	1478 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1001 39%	9 100%	1465 57%	0 0%	119 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	981 38%	6 100%	1483 58%	0 0%	111 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	968 38%	11 92%	1459 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%
SEP-2019	0 0%	4 0%	1 8%	955 37%	12 92%	1481 58%	0 0%	110 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
OCT-2019	0 0%	4 0%	1 7%	958 37%	13 93%	1489 58%	0 0%	109 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
NOV-2019	0 0%	4 0%	0 0%	941 37%	3 100%	1469 58%	0 0%	101 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
DEC-2019	0 0%	4 0%	0 0%	924 37%	7 100%	1466 59%	0 0%	100 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1438 60%	0 0%	93 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
APR-2020	0 0%	2 0%	0 0%	840 36%	4 80%	1417 60%	1 20%	93 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%
FEB-2020	0	0%	1	0%
MAR-2020	0	0%	1	0%
APR-2020	0	0%	1	0%

Definitions:

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	667 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	223 12%	1 25%	680 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	645 35%	0 0%	222 12%	0 0%	677 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	5 100%	647 35%	0 0%	217 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	633 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	633 35%	0 0%	209 11%	0 0%	657 36%	0 0%	322 18%
AUG-2019	0 0%	1 0%	2 100%	624 35%	0 0%	205 11%	0 0%	647 36%	0 0%	324 18%
SEP-2019	0 0%	1 0%	4 80%	607 34%	0 0%	207 12%	0 0%	622 35%	1 20%	324 18%
OCT-2019	0 0%	1 0%	6 60%	608 35%	1 10%	209 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0 0%	1 0%	5 71%	612 37%	0 0%	208 12%	1 14%	525 31%	1 14%	326 20%
DEC-2019	0 0%	1 0%	3 100%	607 37%	0 0%	203 12%	0 0%	513 31%	0 0%	324 20%
JAN-2020	0 0%	1 0%	2 100%	589 36%	0 0%	202 13%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	16 0%	15 75%	2429 63%	4 20%	729 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2431 63%	5 23%	726 19%	0 0%	40 1%	1 5%	651 17%
MAR-2019	0 0%	27 1%	8 62%	2479 64%	5 38%	745 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2493 64%	3 21%	736 19%	0 0%	36 1%	3 21%	636 16%
MAY-2019	0 0%	27 1%	19 68%	2554 64%	6 21%	746 19%	0 0%	37 1%	3 11%	634 16%
JUN-2019	0 0%	27 1%	10 77%	2556 65%	3 23%	743 19%	0 0%	37 1%	0 0%	624 16%
JUL-2019	0 0%	27 1%	13 81%	2603 65%	3 19%	755 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2647 65%	1 4%	755 19%	0 0%	36 1%	3 11%	625 15%
SEP-2019	0 0%	28 1%	7 47%	2648 65%	6 40%	757 19%	0 0%	37 1%	2 13%	627 15%
OCT-2019	0 0%	28 1%	13 87%	2717 66%	1 7%	758 18%	0 0%	34 1%	1 7%	628 15%
NOV-2019	3 13%	88 2%	16 70%	2741 65%	4 17%	770 18%	0 0%	33 1%	0 0%	621 15%
DEC-2019	12 63%	230 5%	6 32%	2717 64%	1 5%	744 18%	0 0%	33 1%	0 0%	606 14%
JAN-2020	9 50%	421 10%	7 39%	2689 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2646 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2624 58%	1 4%	624 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	830 18%	6 43%	2591 57%	1 7%	608 13%	0 0%	29 1%	0 0%	544 12%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1830	24.75	1481	20.03	3061	41.40	100	1.35	53	0.72	868	11.74
FEB-2019	1802	24.46	1478	20.06	3072	41.69	99	1.34	49	0.67	868	11.78
MAR-2019	1794	24.22	1471	19.86	3124	42.18	98	1.32	50	0.68	870	11.75
APR-2019	1760	23.92	1458	19.82	3135	42.61	100	1.36	48	0.65	857	11.65
MAY-2019	1773	23.91	1448	19.53	3196	43.10	97	1.31	45	0.61	857	11.56
JUN-2019	1739	23.63	1438	19.54	3195	43.42	95	1.29	48	0.65	844	11.47
JUL-2019	1713	23.24	1427	19.36	3236	43.90	92	1.25	48	0.65	855	11.60
AUG-2019	1686	22.89	1402	19.03	3295	44.73	94	1.28	50	0.68	839	11.39
SEP-2019	1698	23.14	1361	18.54	3298	44.94	93	1.27	51	0.69	838	11.42
OCT-2019	1703	23.04	1339	18.12	3357	45.43	93	1.26	52	0.70	846	11.45
NOV-2019	1667	22.70	1272	17.32	3424	46.63	91	1.24	50	0.68	839	11.43
DEC-2019	1644	22.39	1248	16.99	3484	47.44	92	1.25	48	0.65	828	11.27
JAN-2020	1616	21.96	1209	16.43	3564	48.44	87	1.18	56	0.76	826	11.23
FEB-2020	1573	21.45	1154	15.74	3647	49.74	85	1.16	59	0.80	814	11.10
MAR-2020	1544	20.89	1134	15.34	3756	50.81	85	1.15	51	0.69	822	11.12
APR-2020	1528	20.59	1129	15.21	3814	51.39	85	1.15	50	0.67	815	10.98

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	21	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	15	0	0	2	4	7	530
OCT-2019	13	1	1	4	4	3	380
NOV-2019	17	4	1	1	1	10	520
DEC-2019	12	0	2	4	2	4	350
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	9	0	1	3	0	5	672

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start







**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2019	12252	3830
FEB-2019	12260	3829
MAR-2019	12290	3859
APR-2019	12316	3882
MAY-2019	12332	3883
JUN-2019	12332	3888
JUL-2019	12349	3903
AUG-2019	12381	3920
SEP-2019	12399	3937
OCT-2019	12433	3961
NOV-2019	12455	3970
DEC-2019	12479	3985
JAN-2020	12535	4031
FEB-2020	12566	4048
MAR-2020	12566	4038
APR-2020	12545	4014

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved

**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
April 2020

N = 7421

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY









3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2020

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2020

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2020

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2020

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	7	7	5
	35-49	9	10	5
	50+	27	39	19
	<b>Total HSDA:</b>	<b>43</b>	<b>56</b>	<b>29</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>73</b>	<b>97</b>	<b>56</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>367</b>	<b>498</b>	<b>285</b>	
THOMPSON/CARIBOO/ SHUSWAP	20-34	22	22	14
	35-49	64	69	51
	50+	108	177	81
	<b>Total HSDA:</b>	<b>194</b>	<b>268</b>	<b>146</b>
<b>Total HA:</b>		<b>677</b>	<b>919</b>	<b>516</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>677</b>	<b>919</b>	<b>516</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	541	734	415
Female	136	185	101

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	516	55	620	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)







### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	20	12
	5 years or more	11	6
	<5 years	12	11
	<b>Total HSDA:</b>	<b>43</b>	<b>29</b>
KOOTENAY BOUNDARY	10 years or more	45	34
	5 years or more	16	11
	<5 years	12	11
	<b>Total HSDA:</b>	<b>73</b>	<b>56</b>
OKANAGAN	10 years or more	230	168
	5 years or more	72	62
	<5 years	65	55
	<b>Total HSDA:</b>	<b>367</b>	<b>285</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	112	82
	5 years or more	42	37
	<5 years	40	27
	<b>Total HSDA:</b>	<b>194</b>	<b>146</b>
<b>Total HA:</b>		<b>677</b>	<b>516</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	407	296
5 years or more	141	116
<5 years	129	104
<b>Total HA:</b>	<b>677</b>	<b>516</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	46	64	15	26
KOOTENAY BOUNDARY	75	123	26	47
OKANAGAN	222	932	59	287
THOMPSON/CARIBOO/SHUSWAP	139	519	37	137
<b>Total:</b>	<b>482</b>	<b>1638</b>	<b>137</b>	<b>497</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>93</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	33	35	26
	35-49	99	109	75
	50+	242	318	193
	<b>Total HSDA:</b>	<b>380</b>	<b>468</b>	<b>300</b>
FRASER NORTH	0-19	7	7	*
	20-34	114	114	*
	35-49	347	375	*
	50+	581	910	*
	<b>Total HSDA:</b>	<b>1049</b>	<b>1406</b>	<b>797</b>
FRASER SOUTH	0-19	6	6	*
	20-34	111	113	*
	35-49	330	375	*
	50+	550	812	*
	<b>Total HSDA:</b>	<b>997</b>	<b>1306</b>	<b>796</b>
<b>Total HA:</b>		<b>2426</b>	<b>3180</b>	<b>1893</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	19	19	12
	20-34	258	262	187
	35-49	776	859	609
	50+	1373	2040	1085
<b>Total HA:</b>		<b>2426</b>	<b>3180</b>	<b>1893</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1839	2435	1443
Female	587	745	450

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1893	52	630	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





#### 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	226	178
	5 years or more	75	60
	<5 years	79	62
	<b>Total HSDA:</b>	<b>380</b>	<b>300</b>
FRASER NORTH	10 years or more	593	422
	5 years or more	251	203
	<5 years	205	172
	<b>Total HSDA:</b>	<b>1049</b>	<b>797</b>
FRASER SOUTH	10 years or more	569	446
	5 years or more	219	169
	<5 years	209	181
	<b>Total HSDA:</b>	<b>997</b>	<b>796</b>
<b>Total HA:</b>		<b>2426</b>	<b>1893</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1388	1046
	5 years or more	545	432
	<5 years	493	415
<b>Total HA:</b>		<b>2426</b>	<b>1893</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	143	496	30	51
FRASER NORTH	252	1584	51	237
FRASER SOUTH	219	1492	47	437
<b>Total:</b>	<b>614</b>	<b>3572</b>	<b>128</b>	<b>725</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	208
FRASER NORTH	655
FRASER SOUTH	482
<b>Total:</b>	<b>1345</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>345</b>	<b>495</b>
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>180</b>	<b>229</b>
VANCOUVER	0-19	21	21	7
	20-34	456	471	323
	35-49	1360	1531	979
	50+	2847	4883	2072
	<b>Total HSDA:</b>	<b>4684</b>	<b>6906</b>	<b>3381</b>
<b>Total HA:</b>		<b>5209</b>	<b>7630</b>	<b>3810</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	25	25	9
	20-34	514	530	369
	35-49	1485	1668	1078
	50+	3185	5407	2354
<b>Total HA:</b>		<b>5209</b>	<b>7630</b>	<b>3810</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4604	6705	3359
Female	603	923	451

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3810	54	640	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	192	155
	5 years or more	89	76
	<5 years	64	58
	<b>Total HSDA:</b>	<b>345</b>	<b>289</b>
RICHMOND	10 years or more	102	73
	5 years or more	37	30
	<5 years	41	37
	<b>Total HSDA:</b>	<b>180</b>	<b>140</b>
VANCOUVER	10 years or more	2839	1953
	5 years or more	1092	799
	<5 years	753	629
	<b>Total HSDA:</b>	<b>4684</b>	<b>3381</b>
<b>Total HA:</b>		<b>5209</b>	<b>3810</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3133	2181
5 years or more	1218	905
<5 years	858	724
<b>Total HA:</b>	<b>5209</b>	<b>3810</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	179	501	58	170
RICHMOND	44	290	12	93
VANCOUVER	630	10959	214	5258
<b>Total:</b>	<b>853</b>	<b>11750</b>	<b>284</b>	<b>5521</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>109</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA







**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>334</b>	<b>469</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>128</b>	<b>170</b>
SOUTH VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	56
	35-49	*	*	145
	50+	*	*	366
	<b>Total HSDA:</b>		<b>749</b>	<b>1059</b>
<b>Total HA:</b>		<b>1211</b>	<b>1698</b>	<b>943</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>1211</b>	<b>1698</b>	<b>943</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1002	1402	786
Female	209	296	157

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	943	55	570	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	184	149
	5 years or more	79	66
	<5 years	71	56
	<b>Total HSDA:</b>	<b>334</b>	<b>271</b>
NORTH VANCOUVER ISLAND	10 years or more	73	60
	5 years or more	37	29
	<5 years	18	16
	<b>Total HSDA:</b>	<b>128</b>	<b>105</b>
SOUTH VANCOUVER ISLAND	10 years or more	434	305
	5 years or more	161	136
	<5 years	154	126
	<b>Total HSDA:</b>	<b>749</b>	<b>567</b>
<b>Total HA:</b>		<b>1211</b>	<b>943</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	691	514
5 years or more	277	231
<5 years	243	198
<b>Total HA:</b>	<b>1211</b>	<b>943</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	203	872	80	198
NORTH VANCOUVER ISLAND	149	268	51	79
SOUTH VANCOUVER ISLAND	214	1811	47	572
<b>Total:</b>	<b>566</b>	<b>2951</b>	<b>178</b>	<b>849</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	52
NORTH VANCOUVER ISLAND	41
SOUTH VANCOUVER ISLAND	110
<b>Total:</b>	<b>203</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>40</b>	<b>48</b>	<b>25</b>
NORTH WEST	20-34	10	11	7
	35-49	17	33	13
	50+	42	65	35
	<b>Total HSDA:</b>	<b>69</b>	<b>109</b>	<b>55</b>
NORTHERN INTERIOR	0-19	5	5	*
	20-34	24	25	*
	35-49	73	91	*
	50+	90	154	*
	<b>Total HSDA:</b>	<b>192</b>	<b>275</b>	<b>147</b>
<b>Total HA:</b>		<b>301</b>	<b>432</b>	<b>227</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	36	38	*
	35-49	109	146	*
	50+	150	242	*
<b>Total HA:</b>		<b>301</b>	<b>432</b>	<b>227</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	181	265	133
Female	120	167	94

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	227	50	530	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	21	*
	5 years or more	14	*
	<5 years	5	*
	<b>Total HSDA:</b>	<b>40</b>	<b>25</b>
NORTH WEST	10 years or more	34	24
	5 years or more	23	20
	<5 years	12	11
	<b>Total HSDA:</b>	<b>69</b>	<b>55</b>
NORTHERN INTERIOR	10 years or more	79	57
	5 years or more	64	55
	<5 years	49	35
	<b>Total HSDA:</b>	<b>192</b>	<b>147</b>
<b>Total HA:</b>		<b>301</b>	<b>227</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	134	93
	5 years or more	101	84
	<5 years	66	50
<b>Total HA:</b>		<b>301</b>	<b>227</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries NORTHERN Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	42	64	8	9
NORTH WEST	82	164	18	35
NORTHERN INTERIOR	117	472	20	190
<b>Total:</b>	<b>241</b>	<b>700</b>	<b>46</b>	<b>234</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	18
NORTHERN INTERIOR	13
<b>Total:</b>	<b>38</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	24	40	*
	THOMPSON/CARIBOO/SHUSWAP	25	47	*
	<b>Total HA:</b>	<b>61</b>	<b>106</b>	<b>46</b>
FRASER	FRASER EAST	39	49	31
	FRASER NORTH	55	91	44
	FRASER SOUTH	77	110	56
	<b>Total HA:</b>	<b>171</b>	<b>250</b>	<b>131</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	23
	RICHMOND	8	13	6
	VANCOUVER	483	863	388
	<b>Total HA:</b>	<b>516</b>	<b>924</b>	<b>417</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	52	81	44
	NORTH VANCOUVER ISLAND	20	29	18
	SOUTH VANCOUVER ISLAND	40	84	36
	<b>Total HA:</b>	<b>112</b>	<b>194</b>	<b>98</b>
NORTHERN	NORTH EAST	11	13	10
	NORTH WEST	26	57	21
	NORTHERN INTERIOR	74	113	63
	<b>Total HA:</b>	<b>111</b>	<b>183</b>	<b>94</b>
<b>Total:</b>		<b>971</b>	<b>1657</b>	<b>786</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	610	1059	490
Female	361	598	296

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	786	51	480	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.







## Monthly Report

**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Doravirine:** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intelence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





## Monthly Report

**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**Odefsey (ODF):** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





## Monthly Report

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





## Monthly Report

---

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

